Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Assets (2016 - 2025)

Spyre Therapeutics' Non-Current Assets history spans 11 years, with the latest figure at $10000.0 for Q1 2025.

  • For Q1 2025, Non-Current Assets fell 96.96% year-over-year to $10000.0; the TTM value through Dec 2025 reached $10000.0, down 98.53%, while the annual FY2024 figure was $10000.0, 96.98% down from the prior year.
  • Non-Current Assets reached $10000.0 in Q1 2025 per SYRE's latest filing, roughly flat from $10000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.6 million in Q2 2021 to a low of $10000.0 in Q3 2024.
  • Average Non-Current Assets over 5 years is $5.9 million, with a median of $8.1 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: grew 16.03% in 2021, then plummeted 99.24% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $11.0 million in 2021, then fell by 19.47% to $8.9 million in 2022, then plummeted by 96.28% to $331000.0 in 2023, then crashed by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Non-Current Assets are $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q3 2024).